{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:33:15Z","timestamp":1787761995658,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) have dramatically improved chronic myeloid leukemia (CML) prognosis. However, TKIs are associated with dyslipidemia and impaired glucosehomeostasis. Triglyceride-to-high-density lipoprotein cholesterol ratio (TG\/HDL-C) is proposed to be an indicator of insulin resistance and atherogenic index, but there is no research on TG\/HDL-C alterations in patients receiving TKIs for CML. We aimed to evaluate relationships between TKI type\/count, clinical characteristics, and laboratory results (particularly TG\/HDL-C) in CML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A total of 104 patients with chronic phase CML were enrolled in the study. All patients received initial imatinib therapy at 400 mg daily, the type or dose of TKI was then changed according to treatment response and clinical outcomes. Patients were compared with respect to TG\/HDL-C categorization (&gt;2.5 versus &lt;2.5), number of TKIs used, and use of imatinib as the only TKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median TG\/HDL-C was 2.82 (1.03\u201317.33) and this ratio was higher than 2.5 in 59 (56.7%) patients. Patients with high TG\/HDL-C had a significantly higher age than patients with low values (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Recipients of more than one TKI had higher EUTOS risk score and white blood cell (WBC) count (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Recipients of imatinib as the only TKI had higher age, low EOTUS risk score, low WBC, and low neutrophil count (all,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TG\/HDL-C values were not associated with the number of different TKIs used or the use of imatinib only in chronic-phase patients with CML. Further large-scale prospective studies are needed to determine whether TG\/HDL-C can be used for diagnostic or prognostic purposes in TKI recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_755_22","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T06:01:30Z","timestamp":1689314490000},"page":"802-809","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio"],"prefix":"10.4103","volume":"26","author":[{"given":"ET","family":"Erkek","sequence":"first","affiliation":[{"name":"University of Health Sciences Kartal Dr. Lutfi K\u0131rdar City Hospital, Department of Hematology, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AC","family":"Isik","sequence":"additional","affiliation":[{"name":"University of Health Sciences Kartal Dr. Lutfi K\u0131rdar City Hospital, Department of \u0130nternal Medicine, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ipek","sequence":"additional","affiliation":[{"name":"University of Health Sciences Kartal Dr. Lutfi K\u0131rdar City Hospital, Department of Hematology, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AN","family":"Kul","sequence":"additional","affiliation":[{"name":"University of Health Sciences Kartal Dr. Lutfi K\u0131rdar City Hospital, Department of Hematology, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"R1-20240907","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","article-title":"A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R2-20240907","doi-asserted-by":"crossref","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","article-title":"Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017:A systematic analysis for the Global Burden of Disease Study 2017","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"key":"R3-20240907","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10428194.2021.1975191","article-title":"Chronic myeloid leukemia with pure erythroid leukemia blast crisis","volume":"63","author":"Jacobs","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R4-20240907","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first-and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients:A real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"R5-20240907","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"R6-20240907","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia:2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"R7-20240907","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies:Tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann Endocrinol"},{"key":"R8-20240907","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.numecd.2021.11.005","article-title":"Triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular events in the general population:A systematic review and meta-analysis of cohort studies","volume":"32","author":"Chen","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R9-20240907","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/diagnostics12020431","article-title":"A Comparative Study of the Triglycerides\/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer","volume":"12","author":"Crocetto","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R10-20240907","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"R11-20240907","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment:The EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"(Suppl 2)","key":"R12-20240907","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia:An update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"key":"R13-20240907","doi-asserted-by":"crossref","first-page":"109076","DOI":"10.1016\/j.celrep.2021.109076","article-title":"Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response","volume":"35","author":"Vaena","year":"2021","journal-title":"Cell Rep"},{"key":"R14-20240907","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.7150\/jca.15776","article-title":"Pretreatment TG\/HDL-C ratio is superior to triacylglycerol level as an independent prognostic factor for the survival of triple negative breast Cancer patients","volume":"7","author":"Dai","year":"2016","journal-title":"J Cancer"},{"key":"R15-20240907","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbrc.2018.02.097","article-title":"Lipid metabolism and lipophagy in cancer","volume":"504","author":"Maan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R16-20240907","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/curroncol29090481","article-title":"Preoperative serum triglyceride to high-density lipoprotein cholesterol ratio can predict prognosis in non-small cell lung cancer:A multicenter retrospective cohort study","volume":"29","author":"Li","year":"2022","journal-title":"Curr Oncol"},{"key":"R17-20240907","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.bjc.6605264","article-title":"Serum triglyceride concentrations and cancer risk in a large cohort study in Austria","volume":"101","author":"Ulmer","year":"2009","journal-title":"Br J Cancer"},{"key":"R18-20240907","doi-asserted-by":"crossref","first-page":"e0142669","DOI":"10.1371\/journal.pone.0142669","article-title":"Serum lipids and breast cancer risk:A meta-analysis of prospective cohort studies","volume":"10","author":"Ni","year":"2015","journal-title":"PloS One"},{"key":"R19-20240907","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12944-019-1174-5","article-title":"Altered HDL particle in sickle cell disease:Decreased cholesterol content is associated with hemolysis, whereas decreased Apolipoprotein A1 is linked to inflammation","volume":"18","author":"Yalcinkaya","year":"2019","journal-title":"Lipids Health Dis"},{"key":"R20-20240907","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.semcancer.2020.10.007","article-title":"HDL and cancer-causality still needs to be confirmed?Update 2020","volume":"73","author":"Ganjali","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"R21-20240907","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1172\/JCI57559","article-title":"ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice","volume":"121","author":"Murphy","year":"2011","journal-title":"J Clin Invest"},{"key":"R22-20240907","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/00365513.2019.1627578","article-title":"Oxysterol concentrations are associated with cholesterol concentrations and anemia in pediatric patients with sickle cell disease","volume":"79","author":"Yalcinkaya","year":"2019","journal-title":"Scand J Clin Lab Invest"},{"key":"R23-20240907","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.7150\/jca.35939","article-title":"Triglyceride-to-high density lipoprotein cholesterol ratio predicts clinical outcomes in patients with gastric cancer","volume":"10","author":"Sun","year":"2019","journal-title":"J Cancer"},{"key":"R24-20240907","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/kjm2.12033","article-title":"Pretreatment triglycerides-to-high density lipoprotein cholesterol ratio in postmenopausal women with endometrial cancer","volume":"35","author":"Luo","year":"2019","journal-title":"Kaohsiung J Med Sci"},{"key":"R25-20240907","doi-asserted-by":"crossref","first-page":"03000605221117211","DOI":"10.1177\/03000605221117211","article-title":"Prognostic significance of TG\/HDL-C and non-HDL-C\/HDL-C ratios in patients with non-small cell lung cancer:A retrospective study","volume":"50","author":"Kong","year":"2022","journal-title":"J Int Med Res"},{"key":"R26-20240907","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase:ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"R27-20240907","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first-or second-line therapy for chronic myelogenous leukemia in the US","volume":"34","author":"Franklin","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"R28-20240907","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","author":"Agostino","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"R29-20240907","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"R30-20240907","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajco.12473","article-title":"A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma","volume":"12","author":"Song","year":"2016","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_755_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:14:17Z","timestamp":1787760857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_755_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_755_22","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}